Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2023-06-24
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-01 (study day 26); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-12 (study day 68); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 82); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-01-04 (study day 182); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-17 (study day 226); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.